Tweet
VolitionRX Ltd (NYSEAMERICAN:VNRX) â€“ Analysts at Oppenheimer lifted their FY2021 earnings per share estimates for VolitionRX in a research note issued on Tuesday, August 14th. Oppenheimer analyst M. Breidenbach now expects that the medical research company will post earnings per share of $0.43 for the year, up from their prior estimate of $0.39. Oppenheimer also issued estimates for VolitionRX's FY2022 earnings at $0.68 EPS. Get VolitionRX alerts:
VNRX has been the subject of several other research reports. Maxim Group assumed coverage on VolitionRX in a research note on Wednesday, May 16th. They set a "buy" rating and a $6.00 price target for the company. Benchmark restated a "buy" rating and set a $5.00 price target (down previously from $7.00) on shares of VolitionRX in a research note on Monday, May 14th. Shares of NYSEAMERICAN VNRX opened at $1.73 on Thursday. VolitionRX has a twelve month low of $1.44 and a twelve month high of $4.00.
VolitionRX (NYSEAMERICAN:VNRX) last issued its quarterly earnings data on Monday, August 13th. The medical research company reported ($0.15) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.16) by $0.01.
About VolitionRX
VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers worldwide. The company develops 39 epigenetic Nu.Q blood assays based on its Nucleosomics biomarker discovery platform. VolitionRX Limited is based in Singapore.
Featured Article: Technical Analysis Receive News & Ratings for VolitionRX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRX and related companies with MarketBeat.com's FREE daily email newsletter 